Ironwood Pharmaceuticals Stock Forecast for 2023 - 2025 - 2030
Updated on 09/26/2023
Ironwood Pharmaceuticals Stock Forecast and Price Target
The average price target for Ironwood Pharmaceuticals's stock lately set by several renowned analysts is $12.50, which would result in a potential upside of approximately 46.54% if it reaches this mark by December 31, 2023. This estimation is based on a high estimate of $16.00 and a low estimate of $9.00. If you're looking for Ironwood Pharmaceuticals (IRWD) stock information, you might also want to check out Adamis Pharmaceuticals (NasdaqCM:ADMP).
46.54% Upside
Ironwood Pharmaceuticals Fair Value Forecast for 2023 - 2025 - 2030
In the last two years, Ironwood Pharmaceuticals's Price has grown, increasing from $6.73 to $14.19 – an increase of 110.91%. According to 0 major analysts, Ironwood Pharmaceuticals's Fair Value will fall by 31.39% in the next year, reaching $9.73. Professionals believe that By 2030, Ironwood Pharmaceuticals's Fair Value will fall to $10.60– a 25.25% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| AZN Stock Forecast | AstraZeneca PLC | Buy |
8
|
£11.14k | £153.20 | -98.60% |
| 4502 Stock Forecast | Takeda Pharmaceutical Company | Outperform |
16
|
¥4.08k | ¥0.00 | 7.84% |
| PCRX Stock Forecast | Pacira BioSciences | Outperform |
16
|
$32.82 | $79.67 | 137.66% |
| SUPN Stock Forecast | Supernus Pharmaceuticals | Outperform |
16
|
$30.06 | $35.50 | 13.11% |
| MNKP.F Stock Forecast | Mallinckrodt | - |
12
|
$19.00 | $1.50 | 9.11% |
Ironwood Pharmaceuticals Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Ironwood Pharmaceuticals's Revenue has seen a drop from $428.41M to $413.75M – a 3.42% decrease. According to 0 major analysts, Ironwood Pharmaceuticals's Revenue will fall by 0.58% in the next year, reaching $411.35M. Professionals believe that By 2030, Ironwood Pharmaceuticals's Revenue will fall to $410.89M– a 0.69% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| NKTR Stock Forecast | Nektar Therapeutics | Hold |
11
|
$0.61 | $29.50 | 654.10% |
| COLL Stock Forecast | Collegium Pharmaceutical | Buy |
11
|
$22.35 | $27.50 | 29.75% |
| NasdaqGS:BDSI Stock Forecast | BioDelivery Sciences Internati... | - |
11
|
$5.59 | $10.00 | 78.89% |
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| ANIP Stock Forecast | ANI Pharmaceuticals | Outperform |
13
|
$58.20 | $61.67 | -22.68% |
| ASRT Stock Forecast | Assertio Holdings | Outperform |
8
|
$2.60 | $5.83 | 130.77% |
| RDHL Stock Forecast | RedHill Biopharma | Buy |
0
|
$0.95 | $0.00 | 847.37% |
Ironwood Pharmaceuticals Free Cash Flow Forecast for 2023 - 2025 - 2030
In the last two years, Ironwood Pharmaceuticals's Free Cash Flow has grown by 38575.00%, from $-680.00k to $261.63M. In the following year, 0 experts forecast that Ironwood Pharmaceuticals's Free Cash Flow will decrease by 57.58%, to $110.97M. In 2030, professionals predict that Ironwood Pharmaceuticals's Free Cash Flow will decrease by 35.60%, to $168.50M.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| ACRX Stock Forecast | AcelRx Pharmaceuticals | Outperform |
6
|
$0.29 | $4.25 | 1279.31% |
| AQST Stock Forecast | Aquestive Therapeutics | Outperform |
0
|
$2.93 | $0.00 | 241.30% |
| CPIX Stock Forecast | Cumberland Pharmaceuticals | - |
0
|
$2.23 | $0.00 | 10.76% |
Ironwood Pharmaceuticals Net Income Forecast for 2023 - 2025 - 2030
In the last two years, Ironwood Pharmaceuticals's Net Income has grown, increasing from $21.51M to $528.45M – a growth of 2356.76%. According to 0 analysts, Ironwood Pharmaceuticals's Net Income will fall by 79.85% in the next year, reaching $106.47M. Professionals believe that By 2030, Ironwood Pharmaceuticals's Net Income will fall to $487.26M – a 7.79% decrease from its current value.
Ironwood Pharmaceuticals EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Ironwood Pharmaceuticals's EBITDA has grown from $129.05M to $234.04M – a 81.36% increase. 0 analysts predict Ironwood Pharmaceuticals's EBITDA will decrease by 27.38% in the next year, reaching $169.95M. By 2030, professionals predict that Ironwood Pharmaceuticals's EBITDA will decrease by 22.68%, to $180.95M.
Ironwood Pharmaceuticals EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Ironwood Pharmaceuticals's EBIT has grown by 88.32%, rising from $123.47M to $232.52M. For the following year, the 0 analysts predict that Ironwood Pharmaceuticals's EBIT will drop by 28.54%, reaching $166.17M. In 2030, the professionals' prediction is that IRWD's EBIT will decrease by 23.44%, reaching $178.01M.
Ironwood Pharmaceuticals EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last two years, Ironwood Pharmaceuticals's EPS has grown, increasing from $0.55 to $1.16 – an increase of 110.91%. According to 0 major analysts, Ironwood Pharmaceuticals's EPS will fall by 31.39% in the next year, reaching $0.80. Professionals believe that By 2030, Ironwood Pharmaceuticals's EPS will fall to $0.87– a 25.25% decrease from its current value.